Patients with moderate to severe papulopustular rosacea have better outcomes with low-dose minocycline than with placebo and ...

Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to management that emphasizes patient education and individualized treatment ...

A study found that DFD-29 was more effective than both doxycycline and placebo, with a favorable risk-benefit profile for ...

The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of rosacea in ...

Some people have found success using doxycycline for rosacea. Doxycycline is a tetracycline antibiotic commonly prescribed ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder. The new capsule formulation of the ...

If you frequently experience facial redness, irritation and small bumps, you may have rosacea. According to the American Academy of Dermatology, rosacea impacts more than 14 million people in the ...

In the Minocycline Versus Oracea® in Rosacea-1 (MVOR-1) and Minocycline Versus Oracea in Rosacea-2 (MVOR-2) trials, subjects were randomized to receive DFD-29, Oracea, or placebo. The co-primary ...

Journey Medical (DERM) announced that full results from two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator ...

“As the lowest-dose oral minocycline on the market, Emrosi delivers significantly superior clinical outcomes for rosacea compared to placebo and Oracea® while maintaining a comparable safety profil ...

U.S. FDA approved EmrosiTM (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the tr ...